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Rationale
Urticaria is a common condition that affects as many as
2 5 %o fp e o p l ea ts o m et i m ei nt h e i rl i v e s .C h r o n i c
recurrent urticaria and angioedema can be frustrating
and often refractory to conventional treatment. The pur-
pose of this study was to evaluate the efficacy of Sulfasa-
lazine in the treatment of unremitting recurrent
urticaria and angioedema.
Methods
We performed a retrospective chart review of 20 patients
with chronic idiopathic urticaria/angioedema (CIU) trea-
ted with Sulfasalazine as adjunctive therapy at the Winni-
peg Health Science Centre from 2005-2009. We recorded
demographic data, response to Sulfasalazine, presence of
the IgE receptor antibody, and side effects.
Results
20 patients were treated with Sulfasalazine as adjunctive
therapy and 1 patient was lost to follow up. The patient’s
ages ranged between 27-75 years with a mean of 48 years
and 10 (50%) were female. IgE receptor antibody status
was determined in 12 patients and 6 patients were posi-
tive. Out of the 19 patients who are still being followed,
10(52.6%) failed to respond to the Sulfasalazine, and 9
(47.4%) responded to Sulfasalazine with 2 partial respon-
ders and 7 complete responders. Side effects noted
included: increased liver function tests, leucopenia, dys-
pepsia, flatulence nausea, pyrosis and a rash.
Conclusions
Sulfasalazine may be a useful adjunctive treatment for
patients with CIU. Larger blinded, placebo controlled
trials are required to confirm its efficacy.
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